Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 36

1.

The Raf/MEK/ERK pathway can govern drug resistance, apoptosis and sensitivity to targeted therapy.

Abrams SL, Steelman LS, Shelton JG, Wong EW, Chappell WH, Bäsecke J, Stivala F, Donia M, Nicoletti F, Libra M, Martelli AM, McCubrey JA.

Cell Cycle. 2010 May;9(9):1781-91. Epub 2010 May 10.

2.

Enhancing therapeutic efficacy by targeting non-oncogene addicted cells with combinations of signal transduction inhibitors and chemotherapy.

Abrams SL, Steelman LS, Shelton JG, Chappell W, Bäsecke J, Stivala F, Donia M, Nicoletti F, Libra M, Martelli AM, McCubrey JA.

Cell Cycle. 2010 May;9(9):1839-46. Epub 2010 May 15.

3.

Dominant roles of the Raf/MEK/ERK pathway in cell cycle progression, prevention of apoptosis and sensitivity to chemotherapeutic drugs.

Steelman LS, Abrams SL, Shelton JG, Chappell WH, Bäsecke J, Stivala F, Donia M, Nicoletti F, Libra M, Martelli AM, McCubrey JA.

Cell Cycle. 2010 Apr 15;9(8):1629-38. Epub 2010 Apr 15.

4.

Synergy between an IGF-1R antibody and Raf/MEK/ERK and PI3K/Akt/mTOR pathway inhibitors in suppressing IGF-1R-mediated growth in hematopoietic cells.

Bertrand FE, Steelman LS, Chappell WH, Abrams SL, Shelton JG, White ER, Ludwig DL, McCubrey JA.

Leukemia. 2006 Jul;20(7):1254-60. Epub 2006 Apr 27.

PMID:
16642049
5.

Development of a conditional in vivo model to evaluate the efficacy of small molecule inhibitors for the treatment of Raf-transformed hematopoietic cells.

Konopleva M, Shi Y, Steelman LS, Shelton JG, Munsell M, Marini F, McQueen T, Contractor R, McCubrey JA, Andreeff M.

Cancer Res. 2005 Nov 1;65(21):9962-70.

6.

The epidermal growth factor receptor gene family as a target for therapeutic intervention in numerous cancers: what's genetics got to do with it?

Shelton JG, Steelman LS, Abrams SL, Bertrand FE, Franklin RA, McMahon M, McCubrey JA.

Expert Opin Ther Targets. 2005 Oct;9(5):1009-30. Review.

PMID:
16185155
7.

Conditional EGFR promotes cell cycle progression and prevention of apoptosis in the absence of autocrine cytokines.

Shelton JG, Steelman LS, Abrams SL, White ER, Akula SM, Franklin RA, Bertrand FE, McMahon M, McCubrey JA.

Cell Cycle. 2005 Jun;4(6):822-30. Epub 2005 Jun 7.

PMID:
15917660
8.

Effects of endogenous epidermal growth factor receptor signaling on DNA synthesis and ERK activation in a cytokine-dependent hematopoietic cell line.

Shelton JG, Steelman LS, Abrams SL, White ER, Akula SM, Bertrand FE, Franklin RA, McCubrey JA.

Cell Cycle. 2005 Jun;4(6):818-21. Epub 2005 Jun 7.

PMID:
15908804
9.
10.
11.

Raf and VEGF: emerging therapeutic targets in Kaposi's sarcoma-associated herpesvirus infection and angiogenesis in hematopoietic and nonhematopoietic tumors.

Hamden KE, Whitman AG, Ford PW, Shelton JG, McCubrey JA, Akula SM.

Leukemia. 2005 Jan;19(1):18-26. Review.

PMID:
15470486
12.

Effects of a conditionally active v-ErbB and an EGF-R inhibitor on transformation of NIH-3T3 cells and abrogation of cytokine dependency of hematopoietic cells.

McCubrey JA, Shelton JG, Steelman LS, Franklin RA, Sreevalsan T, McMahon M.

Oncogene. 2004 Oct 14;23(47):7810-20.

PMID:
15361836
13.

Raf promotes human herpesvirus-8 (HHV-8/KSHV) infection.

Akula SM, Ford PW, Whitman AG, Hamden KE, Shelton JG, McCubrey JA.

Oncogene. 2004 Jul 1;23(30):5227-41.

PMID:
15122343
14.

Ability of the activated PI3K/Akt oncoproteins to synergize with MEK1 and induce cell cycle progression and abrogate the cytokine-dependence of hematopoietic cells.

Shelton JG, Blalock WL, White ER, Steelman LS, McCubrey JA.

Cell Cycle. 2004 Apr;3(4):503-12. Epub 2004 Apr 1.

PMID:
15004527
15.

JAK/STAT, Raf/MEK/ERK, PI3K/Akt and BCR-ABL in cell cycle progression and leukemogenesis.

Steelman LS, Pohnert SC, Shelton JG, Franklin RA, Bertrand FE, McCubrey JA.

Leukemia. 2004 Feb;18(2):189-218. Review.

PMID:
14737178
16.

Synergy between PI3K/Akt and Raf/MEK/ERK pathways in IGF-1R mediated cell cycle progression and prevention of apoptosis in hematopoietic cells.

Shelton JG, Steelman LS, White ER, McCubrey JA.

Cell Cycle. 2004 Mar;3(3):372-9. Epub 2004 Mar 1.

PMID:
14726697
17.

B-raf and insulin synergistically prevent apoptosis and induce cell cycle progression in hematopoietic cells.

Shelton JG, Chang F, Lee JT, Franklin RA, Steelman LS, McCubrey JA.

Cell Cycle. 2004 Feb;3(2):189-96.

PMID:
14712088
18.

Differential effects of kinase cascade inhibitors on neoplastic and cytokine-mediated cell proliferation.

Shelton JG, Moye PW, Steelman LS, Blalock WL, Lee JT, Franklin RA, McMahon M, McCubrey JA.

Leukemia. 2003 Sep;17(9):1765-82.

PMID:
12970777
19.

Signal transduction mediated by the Ras/Raf/MEK/ERK pathway from cytokine receptors to transcription factors: potential targeting for therapeutic intervention.

Chang F, Steelman LS, Lee JT, Shelton JG, Navolanic PM, Blalock WL, Franklin RA, McCubrey JA.

Leukemia. 2003 Jul;17(7):1263-93. Review.

PMID:
12835716
20.

Requirement for the PI3K/Akt pathway in MEK1-mediated growth and prevention of apoptosis: identification of an Achilles heel in leukemia.

Blalock WL, Navolanic PM, Steelman LS, Shelton JG, Moye PW, Lee JT, Franklin RA, Mirza A, McMahon M, White MK, McCubrey JA.

Leukemia. 2003 Jun;17(6):1058-67.

PMID:
12764369
21.

Effects of the RAF/MEK/ERK and PI3K/AKT signal transduction pathways on the abrogation of cytokine-dependence and prevention of apoptosis in hematopoietic cells.

Shelton JG, Steelman LS, Lee JT, Knapp SL, Blalock WL, Moye PW, Franklin RA, Pohnert SC, Mirza AM, McMahon M, McCubrey JA.

Oncogene. 2003 Apr 24;22(16):2478-92.

PMID:
12717425
22.

Involvement of PI3K/Akt pathway in cell cycle progression, apoptosis, and neoplastic transformation: a target for cancer chemotherapy.

Chang F, Lee JT, Navolanic PM, Steelman LS, Shelton JG, Blalock WL, Franklin RA, McCubrey JA.

Leukemia. 2003 Mar;17(3):590-603. Review.

PMID:
12646949
23.

Elucidation of signal transduction pathways by retroviral infection of cells with modified oncogenes.

Steelman LS, Blalock WL, Wang XY, Moye PW, Lee JT, Shelton JG, Navolanic PM, Davis JM, Knapp SL, Franklin RA, White MK, McCubrey JA.

Methods Mol Biol. 2003;218:221-52.

PMID:
12616724
24.

Elucidation of signal transduction pathways by transfection of cells with modified oncogenes.

Steelman LS, Blalock WL, Wang XY, Moye PW, Lee JT, Shelton JG, Navolanic PM, Davis JM, Knapp SL, Franklin RA, White MK, McCubrey JA.

Methods Mol Biol. 2003;218:203-20.

PMID:
12616723
25.

Fibroblastic, hematopoietic, and hormone responsive epithelial cell lines and culture conditions for elucidation of signal transduction and drug resistance pathways by gene transfer.

Steelman LS, Blalock WL, Wang XY, Moye PW, Lee JT, Shelton JG, Navolanic PM, Davis JM, Knapp SL, Franklin RA, White MK, McCubrey JA.

Methods Mol Biol. 2003;218:185-201. Review.

PMID:
12616722
26.

Regulation of cell cycle progression and apoptosis by the Ras/Raf/MEK/ERK pathway (Review).

Chang F, Steelman LS, Shelton JG, Lee JT, Navolanic PM, Blalock WL, Franklin R, McCubrey JA.

Int J Oncol. 2003 Mar;22(3):469-80. Review.

PMID:
12579299
27.

Importance of the T cell receptor alpha-chain transmembrane distal region for assembly with cognate subunits.

Shelton JG, Gülland S, Nicolson K, Kearse KP, Bäckström BT.

Mol Immunol. 2001 Aug;38(4):259-65.

PMID:
11566319
28.

Interactions between the PI3K and Raf signaling pathways can result in the transformation of hematopoietic cells.

McCubrey JA, Lee JT, Steelman LS, Blalock WL, Moye PW, Chang F, Pearce M, Shelton JG, White MK, Franklin RA, Pohnert SC.

Cancer Detect Prev. 2001;25(4):375-93.

PMID:
11531015
29.

Synergistic effects of pi3k/akt on abrogation of cytokine-dependency induced by oncogenic raf.

McCubrey JA, Steelman LS, Blalock WL, Lee JT, Moye PW, Chang F, Pearce M, Shelton JG, White MK, Franklin RA, Pohnert SC.

Adv Enzyme Regul. 2001;41:289-323. No abstract available.

PMID:
11384752
30.

Oncogene-dependent engraftment of human myeloid leukemia cells in immunosuppressed mice.

Kiser M, McCubrey JA, Steelman LS, Shelton JG, Ramage J, Alexander RL, Kucera GL, Pettenati M, Willingham MC, Miller MS, Frankel AE.

Leukemia. 2001 May;15(5):814-8.

31.

Effects of deregulated Raf activation on integrin, cytokine-receptor expression and the induction of apoptosis in hematopoietic cells.

Weinstein-Oppenheimer C, Steelman LS, Algate PA, Blalock WL, Burrows C, Hoyle PE, Lee JT, Moye PW, Shelton JG, Franklin R, McCubrey JA.

Leukemia. 2000 Nov;14(11):1921-38.

32.

INTRA-UTERINE DEATH DUE TO FOETAL ERYTHROBLASTOSIS

Townsend L, Shelton JG.

Aust N Z J Obstet Gynaecol. 1964 Jun;4(2):85-9. No abstract available.

PMID:
14173829
33.

Induction of labour in the Rh-immunized patient.

TOWNSEND SL, MACKAY EV, SHELTON JG, KRIEGER VI, CAMPBELL KI.

J Obstet Gynaecol Br Commonw. 1961 Jun;68:382-99. No abstract available.

PMID:
13777786
34.

Aplastic anaemia and agranulocytosis following chlorpromazine therapy.

SHELTON JG, KINGSTON WR, McRAE C.

Med J Aust. 1960 Jan 23;47(1):130-1. No abstract available.

PMID:
14445798
35.

Erythroblastosis foetalis due to O-A incompatibility.

SHELTON JG.

Med J Aust. 1958 Nov 29;45(22):734-5. No abstract available.

PMID:
13612465
36.

The problem of the isoimmunized Rh-negative mother.

SHELTON JG.

Med J Aust. 1955 Jul 23;42(4):113-6. No abstract available.

PMID:
13253106

Supplemental Content

Loading ...
Support Center